Clinical Trials
14 trialsNCT07416474 2026-04-20
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT07371611 2026-01-28
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04821843 2026-01-21
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT06216301 2025-12-17
LUNAR-2
NovoCure Ltd.
Phase 3 Recruiting
NCT07251582 2025-11-26
LungTime-C02
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT07170995 2025-11-18
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT04906993 2025-09-09
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT05607550 2025-06-22
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
ArriVent BioPharma, Inc.
Phase 3 Active not recruiting
NCT02891824 2025-02-11
ATALANTE
ARCAGY/ GINECO GROUP
Phase 3 Completed
NCT05338970 2025-01-31
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Daiichi Sankyo
Phase 3 Active not recruiting
NCT04428333 2024-10-09
INDUCE-4
GlaxoSmithKline
Phase 3 Terminated
NCT06485557 2024-07-03
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT00144066 2005-09-02
A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer
West Japan Thoracic Oncology Group
Phase 3 Completed